QQ客服 官方微博 反馈留言

	First-line therapy for advanced non-small cell lung cancer with activating EGFR mutation: is combined EGFR-TKIs and chemotherapy a better choice?
	Wang, Shuyun; Gao, Aiqin; Liu, Jie; Sun, Yuping
刊名	CANCER CHEMOTHERAPY AND PHARMACOLOGY
	2018
卷号	81期号:3页码:443-453
关键词	Activating EGFR mutation NSCLC EGFR-TKIs Cytotoxic chemotherapy First-line treatment
DOI	10.1007/s00280-017-3516-1
URL标识	查看原文
公开日期	[db:dc_date_available]
内容类型	期刊论文
URI标识	http://www.corc.org.cn/handle/1471x/4583325
专题	山东大学
作者单位	Shandong Univ, Jinan Cent Hosp, Dept Oncol, 105 Jiefang Rd, Jinan, Shandong, Peoples R China.
推荐引用方式 GB/T 7714	Wang, Shuyun,Gao, Aiqin,Liu, Jie,et al. First-line therapy for advanced non-small cell lung cancer with activating EGFR mutation: is combined EGFR-TKIs and chemotherapy a better choice?[J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY,2018,81(3):443-453.
APA	Wang, Shuyun,Gao, Aiqin,Liu, Jie,&Sun, Yuping.(2018).First-line therapy for advanced non-small cell lung cancer with activating EGFR mutation: is combined EGFR-TKIs and chemotherapy a better choice?.CANCER CHEMOTHERAPY AND PHARMACOLOGY,81(3),443-453.
MLA	Wang, Shuyun,et al."First-line therapy for advanced non-small cell lung cancer with activating EGFR mutation: is combined EGFR-TKIs and chemotherapy a better choice?".CANCER CHEMOTHERAPY AND PHARMACOLOGY 81.3(2018):443-453.

个性服务

查看访问统计

相关权益政策

暂无数据

收藏/分享

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。